A retrospective cohort study of outcome in systemic sclerosis-associated interstitial lung disease

Respiratory Investigation

Volumn 54, Issue 6, 2016, Pages 445-453

  Okamoto, Masaki ^a   Fujimoto, Kiminori ^a   Sadohara, Junko ^a   Furuya, Kiyomi ^a   Kaieda, Shinjiro ^a   Miyamura, Tomoya ^b   Suematsu, Eiichi ^b   Kitasato, Yasuhiko ^a   Kawayama, Tomotaka ^a   Ida, Hiroaki ^a   Ichiki, Masao ^b   Hoshino, Tomoaki ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

Author keywords

Acute exacerbation; Computed tomography; Immunosuppressant; Interstitial lung disease; Systemic sclerosis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; MIZORIBINE; PREDNISOLONE; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; BRONCHIECTASIS; CAUSE OF DEATH; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION TEST; MALE; MONOTHERAPY; MORTALITY RATE; PROGNOSIS; RETROSPECTIVE STUDY; SMOKING; SURVIVAL RATE; SYSTEMIC SCLEROSIS; SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE COURSE; FOLLOW UP; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; PATHOLOGY; X-RAY COMPUTED TOMOGRAPHY;

AGED; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84996761475     PISSN: 22125345     EISSN: 22125353     Source Type: Journal    
DOI: 10.1016/j.resinv.2016.05.004     Document Type: Article

References (32)

1. [1] Bouros, D., Wells, A.U., Nicholson, A.G., et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165 (2002), 1581–1586.
2. [2] Travis, W.D., King, T.E., Bateman, E.D., et al. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165 (2002), 277–304.
3. [3] Raghu, G., Collard, H.R., Egan, J.J., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183 (2011), 788–824.
4. [4] Kim, D.S., Collard, H.R., King, T.E. Jr, Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 3 (2006), 285–292.
5. [5] Travis, W.D., Hunninghake, G., King, T.E. Jr, et al. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med 177 (2008), 338–347.
6. [6] Park, J.H., Kim, D.S., Park, I.N., et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 175 (2007), 705–711.
7. [7] Winstone, T.A., Assayag, D., Wilcox, P.G., et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest J 146 (2014), 422–436.
8. [8] Al-Dhaher, F.F., Pope, J.E., Ouimet, J.M., Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 39 (2010), 269–277.
9. [9] Goh, N.S., Veeraraghavan, S., Desai, S.R., et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 56 (2007), 2005–2012.
10. [10] Kocheril, S.V., Appleton, B.E., Somers, E.C., et al. Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum 53 (2005), 549–557.
11. [11] Johnson, M.A., Kwan, S., Snell, N.J., et al. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 44 (1989), 280–288.
12. [12] Tashkin, D.P., Elashoff, R., Clements, P.J., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354 (2006), 2655–2666.
13. [13] Hoyles, R.K., Ellis, R.W., Wellsbury, J., et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54 (2006), 3962–3970.
14. [14] Alton, E.W., Johnson, M., Turner-Warwick, M., Advanced cryptogenic fibrosing alveolitis: preliminary report on treatment with cyclosporin A. Respir Med 83 (1989), 277–279.
15. [15] Gisslinger, H., Burghuber, O.C., Stacher, G., et al. Efficacy of cyclosporin A in systemic sclerosis. Clin Exp Rheumatol 9 (1991), 383–390.
16. [16] Collard, H.R., Moore, B.B., Flaherty, K.R., et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176 (2007), 636–643.
17. [17] Suda, T., Kaida, Y., Nakamura, Y., et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med 103 (2009), 846–853.
18. [18] Park, I.N., Kim, D.S., Shim, T.S., et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 132 (2007), 214–220.
19. [19] Tachikawa, R., Tomii, K., Ueda, H., et al. Clinical features and outcome of acute exacerbation of interstitial pneumonia: collagen vascular diseases-related versus idiopathic. Respiration 83 (2012), 20–27.
20. [20] Masi, A.T., Rodnan, G.P., Medsger, T.A. Jr, et al. Subcommittee for Scleroderma Criteria of the American Rheumatism Association. Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23 (1980), 581–590.
21. [21] LeRoy, E.C., Black, C., Fleischmajer, R., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15 (1998), 202–205.
22. [22] Hansell, D.M., Bankier, A.A., MacMahon, H., et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology 246 (2008), 697–722.
23. [23] Sumikawa, H., Johkoh, T., Fujimoto, K., et al. Usual interstitial pneumonia and nonspecific interstitial pneumonia: correlation between CT findings at the site of biopsy with pathological diagnoses. Eur J Radiol 81 (2011), 2919–2924.
24. [24] Sumikawa, H., Johkoh, T., Colby, T.V., et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med 177 (2008), 433–439.
25. [25] Fujimoto, K., Taniguchi, H., Johkoh, T., et al. Acute exacerbation of idiopathic pulmonary fibrosis: high-resolution CT scores predict mortality. Eur Radiol 22 (2012), 83–92.
26. [26] Ichikado, K., Suga, M., Müller, N.L., et al. Acute interstitial pneumonia: comparison of high-resolution computed tomography findings between survivors and nonsurvivors. Am J Respir Crit Care Med 165 (2002), 1551–1556.
27. [27] Kohno, N., Awaya, Y., Oyama, T., et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 148 (1993), 637–642.
28. [28] Nannini, C., West, C.P., Erwin, P.J., et al. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther, 10, 2008, R124.
29. [29] Gay, S.E., Kazerooni, E.A., Toews, G.B., et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 157 (1998), 1063–1072.
30. [30] Kim, E.J., Elicker, B.M., Maldonado, F., et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 35 (2010), 1322–1328.
31. [31] Hozumi, H., Nakamura, Y., Johkoh, T., et al. Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open, 13, 2013, e003132.
32. [32] Tyndall, A.J., Bannert, B., Vonk, M., et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69 (2010), 1809–1815.